T2 Biosystems
TTOO
Market cap $26.4M

1.51 USD

+0.08

5.59%

Updated Oct 22, 10:48 AM EDT

1 day

5.59%

5 days

4.86%

1 month

-26.70%

3 months

-70.39%

6 months

-52.22%

Year to date

-72.09%

1 year

-71.02%

5 years

-99.99%

About: T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.

Employees: 113

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2,315% more capital invested

Capital invested by funds: $520K [Q1] → $12.6M (+$12M) [Q2]

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

11% more funds holding

Funds holding: 19 [Q1] → 21 (+2) [Q2]

10.26% more ownership

Funds ownership: 3.51% [Q1] → 13.77% (+10.26%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$5

231%

upside

Avg. target

$5

231%

upside

High target

$5

231%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Canaccord Genuity

Kyle Mikson

31% 1-year accuracy

4 / 13 met price target

231%upside

$5

Hold

Maintained

30 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about TTOO published over the past 30 days

T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript

T2 Biosystems, Inc. (NASDAQ:TTOO ) Business Update Conference Call October 10, 2024 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman and CEO Conference Call Participants Eduardo Martinez - H.C. Wainwright Operator Good day, everyone.

T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript

T2 Biosystems to Host Business Update Call on October 10, 2024

LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at ir@T2Biosystems.com .

T2 Biosystems to Host Business Update Call on October 10, 2024

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems' FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel.

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union.

T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference.

T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

T2 Biosystems to Attend Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2024:

T2 Biosystems to Attend Upcoming Investor Conferences

T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Operator Greetings, and welcome to T2 Biosystems, Inc. Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript

T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor

LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.

T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor

T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024

LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024.

T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

See News Rankings

Charts implemented using Lightweight Charts™